RU2003136733A - Пероральное введение паратиреоидного гормона и кальцитонина - Google Patents
Пероральное введение паратиреоидного гормона и кальцитонина Download PDFInfo
- Publication number
- RU2003136733A RU2003136733A RU2003136733/14A RU2003136733A RU2003136733A RU 2003136733 A RU2003136733 A RU 2003136733A RU 2003136733/14 A RU2003136733/14 A RU 2003136733/14A RU 2003136733 A RU2003136733 A RU 2003136733A RU 2003136733 A RU2003136733 A RU 2003136733A
- Authority
- RU
- Russia
- Prior art keywords
- calcitonin
- pth
- oral administration
- effective amount
- therapeutically effective
- Prior art date
Links
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 title claims abstract 18
- 102000055006 Calcitonin Human genes 0.000 title claims abstract 13
- 108060001064 Calcitonin Proteins 0.000 title claims abstract 13
- 229960004015 calcitonin Drugs 0.000 title claims abstract 13
- 108090000445 Parathyroid hormone Proteins 0.000 title abstract 6
- 102000003982 Parathyroid hormone Human genes 0.000 title abstract 2
- 239000000199 parathyroid hormone Substances 0.000 title abstract 2
- 229960001319 parathyroid hormone Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 claims abstract 8
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 claims 5
- 108010068072 salmon calcitonin Proteins 0.000 claims 5
- 230000011164 ossification Effects 0.000 claims 4
- 230000004936 stimulating effect Effects 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102100036893 Parathyroid hormone Human genes 0.000 abstract 4
- 208000037147 Hypercalcaemia Diseases 0.000 abstract 1
- 206010029148 Nephrolithiasis Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000000148 hypercalcaemia Effects 0.000 abstract 1
- 208000030915 hypercalcemia disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (13)
1. Способ перорального введения эффективной дозы РТН, включающий совместное пероральное введение пациенту, нуждающемуся в РТН, эффективного количества РТН и эффективного количества кальцитонина.
2. Способ по п.1, где кальцитонин означает лососевый кальцитонин.
3. Способ стимуляции остеогенеза, включающий пероральное введение пациенту, нуждающемуся в остеогенезе, терапевтически эффективного количества РТН и терапевтически эффективного количества кальцитонина.
4. Способ по п.3, где кальцитонин означает лососевый кальцитонин.
5. Способ лечения или предупреждения остеопороза, включающий пероральное введение пациенту, нуждающемуся в упомянутом лечении или предупреждении, терапевтически эффективного количества РТН и терапевтически эффективного количества кальцитонина.
6. Способ по п.5, где кальцитонин означает лососевый кальцитонин.
7. Композиция для перорального введения, включающая РТН и кальцитонин.
8. Композиция по п.7, где РТН означает человеческую форму РТН.
9. Композиция по п.8, где кальцитонин означает лососевый кальцитонин.
10. Применение РТН и кальцитонина при получении вводимого перорально лекарственного средства для стимуляции остеогенеза.
11. Применение по п.10, где РТН означает человеческую форму РТН.
12. Применение по п.11, где кальцитонин означает лососевый кальцитонин.
13. Набор для стимуляции остеогенеза, включающий РТН и кальцитонин, применимый для перорального введения, наряду с инструкциями для его перорального введения.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29516901P | 2001-06-01 | 2001-06-01 | |
| US60/295,169 | 2001-06-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003136733A true RU2003136733A (ru) | 2005-05-20 |
| RU2300392C2 RU2300392C2 (ru) | 2007-06-10 |
Family
ID=23136525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003136733/15A RU2300392C2 (ru) | 2001-06-01 | 2002-05-31 | Пероральное введение паратиреоидного гормона и кальцитонина |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20040186050A1 (ru) |
| EP (1) | EP1397156B1 (ru) |
| JP (2) | JP5073153B2 (ru) |
| KR (3) | KR20040007617A (ru) |
| CN (2) | CN1512892A (ru) |
| AT (1) | ATE356631T1 (ru) |
| AU (2) | AU2002344371B2 (ru) |
| BR (1) | BRPI0209748B1 (ru) |
| CA (1) | CA2446929C (ru) |
| CO (1) | CO5540323A2 (ru) |
| CZ (1) | CZ307145B6 (ru) |
| DE (1) | DE60218842T2 (ru) |
| EC (1) | ECSP034858A (ru) |
| ES (1) | ES2282436T3 (ru) |
| HU (1) | HU229613B1 (ru) |
| IL (2) | IL158777A0 (ru) |
| MX (1) | MXPA03011027A (ru) |
| NO (1) | NO330093B1 (ru) |
| NZ (1) | NZ529439A (ru) |
| PL (1) | PL211976B1 (ru) |
| PT (1) | PT1397156E (ru) |
| RU (1) | RU2300392C2 (ru) |
| SK (1) | SK287697B6 (ru) |
| WO (1) | WO2002098453A2 (ru) |
| ZA (1) | ZA200308625B (ru) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL211976B1 (pl) | 2001-06-01 | 2012-07-31 | Novartis Ag | Kompozycja farmaceutyczna do podawania doustnego oraz zastosowanie kompozycji |
| DK1420827T3 (da) | 2001-08-17 | 2009-12-21 | Novartis Ag | 5-CNAC sp, oralt indgivelsesmiddel for parathyroidhormonfragmenter |
| US20050054557A1 (en) * | 2002-05-09 | 2005-03-10 | Goldberg Michael M. | Compositions for delivering parathyroid hormone and calcitonin |
| AU2006292337B8 (en) | 2005-09-19 | 2013-02-07 | Emisphere Technologies, Inc. | Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid |
| GB0522566D0 (en) * | 2005-11-04 | 2005-12-14 | Novartis Ag | Organic compounds |
| CA2628945A1 (en) * | 2005-11-10 | 2007-05-24 | Board Of Control Of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| EP1951207A2 (en) * | 2005-11-17 | 2008-08-06 | Novartis AG | Pharmaceutical composition |
| PT2215047E (pt) | 2007-11-02 | 2014-01-20 | Emisphere Tech Inc | Processo para o tratamento da deficiência de vitamina b12 |
| CA2734442C (en) | 2008-08-18 | 2016-08-16 | Oramed Ltd | Methods and compositions for oral administration of proteins |
| CN104857505A (zh) * | 2008-08-18 | 2015-08-26 | 安特拉贝欧有限公司 | 用于口服给予蛋白质的方法和组合物 |
| AU2009356227A1 (en) | 2009-12-07 | 2012-06-21 | Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| WO2012130193A1 (en) | 2011-03-31 | 2012-10-04 | Zentiva, K.S. | Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration |
| CN104800564A (zh) * | 2015-04-02 | 2015-07-29 | 中国人民解放军济南军区总医院 | 一种治疗血虚不荣型甲状旁腺功能减退症的中药组合物 |
| KR101796604B1 (ko) * | 2016-08-30 | 2017-11-10 | 목포대학교 산학협력단 | 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형 |
| KR102163445B1 (ko) | 2017-11-20 | 2020-10-07 | 주식회사 노브메타파마 | Chp(사이클로-히스프로)를 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물 |
| KR102115353B1 (ko) * | 2019-05-17 | 2020-05-26 | 주식회사 노브메타파마 | Chp(사이클로-히스프로) 및 부갑상선 호르몬을 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4692433A (en) * | 1983-10-12 | 1987-09-08 | The Regents Of The University Of California | Method and composition for regulating serum calcium levels of mammals |
| US5364840A (en) * | 1989-12-05 | 1994-11-15 | Vical, Inc. | Synthetic calcitonin peptides |
| US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| JPH08507070A (ja) * | 1993-02-22 | 1996-07-30 | アルザ・コーポレーション | 活性物質の経口投与のための組成物 |
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| US5866536A (en) * | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5955574A (en) * | 1995-07-13 | 1999-09-21 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. | Analogs of parathyroid hormone |
| US5723577A (en) | 1995-07-13 | 1998-03-03 | Biomeasure Inc. | Analogs of parathyroid hormone |
| DK0993831T3 (da) | 1997-02-07 | 2008-03-25 | Emisphere Tech Inc | Forbindelser og præparater til tilförsel af aktive stoffer |
| TW577759B (en) * | 1997-04-18 | 2004-03-01 | Ipsen Pharma Biotech | Sustained release compositions in the form of microcapsules or implants and the process for their preparation |
| SE9702401D0 (sv) | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
| DE19915272A1 (de) * | 1999-04-03 | 2000-10-05 | Vetter & Co Apotheker | Spritze für medizinische Zwecke |
| WO2000059863A1 (en) * | 1999-04-05 | 2000-10-12 | Emisphere Technologies, Inc. | Disodium salts, monohydrates, and ethanol solvates |
| AU1189301A (en) | 1999-10-29 | 2001-05-14 | Eli Lilly And Company | A pharmaceutical composition having high cell membrane permeability |
| US7049283B2 (en) * | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| PL211976B1 (pl) | 2001-06-01 | 2012-07-31 | Novartis Ag | Kompozycja farmaceutyczna do podawania doustnego oraz zastosowanie kompozycji |
| DK1420827T3 (da) * | 2001-08-17 | 2009-12-21 | Novartis Ag | 5-CNAC sp, oralt indgivelsesmiddel for parathyroidhormonfragmenter |
| US7318925B2 (en) * | 2003-08-08 | 2008-01-15 | Amgen Fremont, Inc. | Methods of use for antibodies against parathyroid hormone |
-
2002
- 2002-05-31 PL PL364089A patent/PL211976B1/pl unknown
- 2002-05-31 WO PCT/EP2002/006017 patent/WO2002098453A2/en active Application Filing
- 2002-05-31 CN CNA028111613A patent/CN1512892A/zh active Pending
- 2002-05-31 KR KR10-2003-7015524A patent/KR20040007617A/ko not_active Ceased
- 2002-05-31 CZ CZ2003-3232A patent/CZ307145B6/cs not_active IP Right Cessation
- 2002-05-31 PT PT02750997T patent/PT1397156E/pt unknown
- 2002-05-31 CA CA2446929A patent/CA2446929C/en not_active Expired - Fee Related
- 2002-05-31 HU HU0400120A patent/HU229613B1/hu not_active IP Right Cessation
- 2002-05-31 CN CN200910258008A patent/CN101837120A/zh active Pending
- 2002-05-31 DE DE60218842T patent/DE60218842T2/de not_active Expired - Lifetime
- 2002-05-31 EP EP02750997A patent/EP1397156B1/en not_active Expired - Lifetime
- 2002-05-31 KR KR1020097022621A patent/KR20090116836A/ko not_active Withdrawn
- 2002-05-31 IL IL15877702A patent/IL158777A0/xx unknown
- 2002-05-31 JP JP2003501491A patent/JP5073153B2/ja not_active Expired - Fee Related
- 2002-05-31 BR BRPI0209748A patent/BRPI0209748B1/pt not_active IP Right Cessation
- 2002-05-31 NZ NZ529439A patent/NZ529439A/en not_active IP Right Cessation
- 2002-05-31 RU RU2003136733/15A patent/RU2300392C2/ru not_active IP Right Cessation
- 2002-05-31 AU AU2002344371A patent/AU2002344371B2/en not_active Ceased
- 2002-05-31 ES ES02750997T patent/ES2282436T3/es not_active Expired - Lifetime
- 2002-05-31 SK SK1475-2003A patent/SK287697B6/sk not_active IP Right Cessation
- 2002-05-31 AT AT02750997T patent/ATE356631T1/de active
- 2002-05-31 KR KR1020127010903A patent/KR101320817B1/ko not_active Expired - Fee Related
- 2002-05-31 MX MXPA03011027A patent/MXPA03011027A/es active IP Right Grant
- 2002-05-31 US US10/478,631 patent/US20040186050A1/en not_active Abandoned
-
2003
- 2003-11-05 ZA ZA200308625A patent/ZA200308625B/xx unknown
- 2003-11-06 IL IL158777A patent/IL158777A/en not_active IP Right Cessation
- 2003-11-18 NO NO20035133A patent/NO330093B1/no not_active IP Right Cessation
- 2003-11-21 EC EC2003004858A patent/ECSP034858A/es unknown
- 2003-12-19 CO CO03111065A patent/CO5540323A2/es not_active Application Discontinuation
-
2006
- 2006-09-29 AU AU2006225157A patent/AU2006225157B2/en not_active Ceased
-
2008
- 2008-01-28 US US12/020,700 patent/US8153587B2/en not_active Expired - Fee Related
-
2010
- 2010-04-22 JP JP2010098631A patent/JP2010189423A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003136733A (ru) | Пероральное введение паратиреоидного гормона и кальцитонина | |
| RU92004521A (ru) | Применение бисфосфонатов и экстракта паращитовидных желез для лечения остеопороза и набор для лечения | |
| RU98111594A (ru) | Фармацевтические композиции, включающие флурбипрофен | |
| EP1064000A4 (en) | VITAMIN D AND ITS ANALOGS FOR THE TREATMENT OF TUMORS AND OTHER HYPERPROLIFERATION DISORDERS | |
| ATE522211T1 (de) | Stabilisierte fibrat-mikropartikel | |
| FI964593A0 (fi) | Oraalisia nestemäisiä alendronaattikokoonpanoja | |
| RU94027680A (ru) | Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы | |
| ATE432289T1 (de) | Glp-1 und behandlungsmethode für diabetes | |
| RU2006105479A (ru) | Применение кальцитонина при остеоартрите | |
| JP2006514092A5 (ru) | ||
| WO2001068125A3 (en) | Methods and compositions for the treatment and prevention of erectile dysfunction | |
| CA2294101A1 (en) | A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor | |
| RU2004107899A (ru) | 5-cnac в качестве агента для пероральной доставки фрагментов паратироидного гормона | |
| JP2005500277A5 (ru) | ||
| JP2003514025A5 (ru) | ||
| RU2006108557A (ru) | Фармацевтические композиции, включающие в себя сочетания производных 2-алкилиден-19-нор-витамина d и паратиреоидного гормона, и способы (лечения) | |
| YU61598A (sh) | Tretmani bolesti uz korišćenje citokina | |
| RU97120700A (ru) | Новое фармакологическое применение антагонистов a-ii рецептора | |
| SE9001308D0 (sv) | Foerfarande foer att behandla och foerebygga foertvining av bensubstans | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| AR025549A1 (es) | Mofetil micofelonato en asociacion con peg-ifn-alfa | |
| CA2403674A1 (en) | The use of t3 for treating congestive heart failure | |
| RU94032102A (ru) | Способ лечения или облегчения боли, связанной со скелетно-мышечными, нервными или кожными заболеваниями, препараты на основе хлорида цезия, способ получения терапевтических препаратов, способ анестезирования | |
| Nikitina et al. | Applicalion of fluoride in complex of periodontal disease. | |
| RU2002129097A (ru) | Комбинированные терапии с использованием активности, повреждающей сосуды |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20180601 |